Ventricular Tachycardia: ECG Diagnosis, Acute Termination, ICD Indications, and Catheter Ablation Strategy

Ventricular Tachycardia: ECG Diagnosis, Acute Termination, ICD Indications, and Catheter Ablation Strategy

Evidence-based clinical guideline covering Brugada and Vereckei wide-complex tachycardia algorithms, pharmacologic termination, primary and secondary ICD prevention, electrical storm management, and substrate-based catheter ablation across ischemic and nonischemic cardiomyopathy.

Author: gomdori, MD Specialty: Cardiology / Electrophysiology Reading time: ~22 min

Executive Summary

Ventricular tachycardia (VT) is a wide-complex rhythm originating below the bundle of His at a rate ≥100 bpm, encompassing a clinical spectrum from idiopathic outflow tract VT in structurally normal hearts to scar-mediated re-entrant VT in ischemic cardiomyopathy with high sudden cardiac death risk. The Brugada and Vereckei algorithms are the standard ECG tools to differentiate VT from supraventricular tachycardia with aberrancy, with the cardinal teaching that any wide-complex tachycardia in a patient with structural heart disease should be presumed VT until proven otherwise. Acute termination follows ACLS — immediate synchronized cardioversion for unstable monomorphic VT, defibrillation for pulseless VT/VF, and pharmacologic termination with procainamide (preferred per PROCAMIO) or amiodarone for stable monomorphic VT. ICD therapy is Class 1 for secondary prevention after sustained VT/VF without reversible cause and for primary prevention in ischemic cardiomyopathy with LVEF ≤35% on optimal GDMT. Catheter ablation has shifted from rescue to first-line therapy: PARTITA showed early ablation after the first appropriate shock reduces death and hospitalization. This guideline integrates 2017 AHA/ACC/HRS and 2022 ESC ventricular arrhythmia recommendations with practical bedside algorithms and refractory storm escalation.

300KUS sudden cardiac deaths per year
80%SCD due to VT/VF
23%Relative SCD reduction with primary-prevention ICD (SCD-HeFT)
70-90%Acute success rate of substrate-based VT ablation

S1. Pathophysiology, Substrate, and Etiologic Classification

Mechanisms of Ventricular Tachycardia

VT arises from three distinct cellular mechanisms: (1) re-entry through anatomic or functional circuits — the dominant mechanism in scar-related VT after myocardial infarction or in cardiomyopathy; (2) triggered activity from early or delayed afterdepolarizations — the basis of torsades de pointes in long QT syndrome and digoxin toxicity; (3) abnormal automaticity from spontaneously depolarizing ectopic foci — characteristic of idiopathic outflow tract VT and accelerated idioventricular rhythm during reperfusion.

Re-entrant VT in ischemic cardiomyopathy depends on surviving myocyte bundles within infarct scar, creating slow-conduction channels surrounded by anatomic conduction block. These channels — visualized as low-voltage zones (<1.5 mV) on electroanatomic mapping with isolated late potentials and fractionated electrograms — form the substrate that catheter ablation targets. In nonischemic cardiomyopathy, scar is typically intramural or epicardial rather than endocardial, requiring epicardial ablation access more frequently.

Etiologic Classification

The 2022 ESC ventricular arrhythmia guidelines classify VT etiology into three broad categories that drive risk stratification and therapy:

CategoryExamplesSCD RiskPrimary Therapy Direction
Structural heart disease (high-risk) Post-MI scar, ischemic CMP, NICM, ARVC, HCM, cardiac sarcoidosis, Chagas High to very high GDMT + ICD + ablation; NICM if LVEF ≤35%
Inherited arrhythmia syndromes Long QT, Brugada, CPVT, short QT, idiopathic VF Variable by genotype/phenotype Beta-blockers (LQT, CPVT), quinidine (Brugada, SQTS), ICD per criteria
Idiopathic VT (structurally normal heart) RVOT VT, LVOT VT, fascicular VT (verapamil-sensitive) Low Beta-blockers or verapamil; catheter ablation for symptomatic/refractory
VT Etiologic Classification Flowchart Decision flowchart classifying ventricular tachycardia by underlying substrate and recommended initial therapy direction Wide-complex tachycardia Confirmed VT (Brugada/Vereckei) Echo / CMR / coronary Structural heart disease? Structural / Scar Ischemic, NICM, HCM, ARVC → ICD ± ablation GDMT optimization Inherited Channelopathy LQT, Brugada, CPVT → Beta-blocker / quinidine ICD by genotype/risk Idiopathic VT RVOT, LVOT, fascicular → BB / verapamil Curative ablation 90%+
Figure 1. Etiologic classification of ventricular tachycardia and initial therapy direction.

Risk Modifiers

LV ejection fraction remains the single strongest predictor of VT-related mortality. Other modifiers include: late gadolinium enhancement (LGE) burden on CMR, syncope history, family history of SCD, NSVT on ambulatory monitoring, and inducibility on programmed electrical stimulation (PES). The MADIT-II trial established LVEF ≤30% post-MI as a primary-prevention ICD threshold (HR 0.69 for mortality), later extended to LVEF ≤35% in NYHA II-III by SCD-HeFT (HR 0.77).

Substrate Drives Strategy

The first decision in any sustained VT patient is identifying substrate: ischemic (reversible? revascularize first), nonischemic (CMR for LGE pattern), or idiopathic (curable by ablation). Failure to characterize substrate leads to inappropriate ICD allocation and missed reversible triggers (ischemia, electrolytes, drug toxicity).

Ventricular Tachycardia — Cardiac Conduction Cardiac conduction system from SA node to Purkinje fibers Ventricular Tachycardia — Cardiac Conduction SA SA Node AV AV Node HIS Bundle of His LBB Left Bundle Branch RBB Right Bundle Branch PURK Purkinje Fibers SA→AV: 50ms | AV delay: 100ms | His→Purkinje: 40ms | Total: ~200ms
Ventricular Tachycardia — Cardiac Conduction

S2. ECG Diagnosis and Risk Stratification

Wide-Complex Tachycardia: VT Until Proven Otherwise

Any regular wide-complex tachycardia (QRS ≥120 ms, HR ≥100 bpm) in a patient with known structural heart disease has ≥90% probability of being VT. The differential includes: (1) VT, (2) SVT with bundle branch block aberrancy, (3) SVT with antegrade conduction over an accessory pathway (pre-excited SVT), and (4) paced rhythm. The cost of treating SVT as VT (cardioversion, amiodarone) is small; the cost of treating VT as SVT (AV nodal blockers — verapamil, diltiazem) can be hemodynamic collapse and degeneration to VF.

Brugada Algorithm (1991) — 4 Sequential Steps

StepCriterionIf YesIf No
1Absence of RS complex in ALL precordial leads (V1-V6)VT (specificity 100%)Go to step 2
2RS interval >100 ms in any precordial leadVTGo to step 3
3AV dissociation presentVTGo to step 4
4Morphology criteria for VT in V1-V2 and V6 (RBBB-like or LBBB-like)VTSVT with aberrancy

Vereckei aVR Algorithm (2008) — Single-Lead Approach

  1. Initial R wave in aVR? → VT (rare; suggests apex-to-base activation)
  2. Initial r or q wave width >40 ms in aVR? → VT
  3. Notch on initial downstroke of predominantly negative QRS in aVR? → VT
  4. Ventricular activation velocity ratio (vi/vt) ≤1? → VT (slow initial then fast terminal = VT; opposite = SVT)

Confirmatory Findings of VT

  • AV dissociation — independent P waves marching through QRS (highly specific but only seen in ~30%)
  • Capture beats — narrow QRS interrupting wide-complex rhythm (sinus impulse capturing ventricle during fortuitous AV node recovery)
  • Fusion beats — intermediate QRS morphology between VT and sinus
  • QRS concordance — all precordial leads positive or all negative
  • QRS duration >140 ms (RBBB pattern) or >160 ms (LBBB pattern)
  • Northwest axis (-90° to +180°)

VT Subtypes by Morphology and Rate

SubtypeDefinitionClinical Significance
Sustained VT≥30 sec or hemodynamic compromiseClass 1 acute termination + workup for ICD
Nonsustained VT (NSVT)≥3 beats, <30 sec, self-terminatesRisk modifier in cardiomyopathy; usually no acute therapy
Monomorphic VTSingle uniform QRS morphologySuggests fixed re-entrant circuit (scar)
Polymorphic VTBeat-to-beat varying morphologySuggests acute ischemia, electrolytes, or LQTS (TdP)
Bidirectional VTAlternating QRS axis (RBBB + alternating LAD/RAD)Digoxin toxicity, CPVT, Andersen-Tawil syndrome
Idioventricular rhythmWide-complex 50-100 bpmReperfusion marker; usually benign, no treatment

Idiopathic VT Localization

Idiopathic VT in structurally normal hearts arises from characteristic foci with predictable ECG morphology — making 12-lead ECG the roadmap for ablation:

  • RVOT VT — LBBB morphology + inferior axis (positive II/III/aVF). Most common idiopathic VT. Adenosine-sensitive. Ablation success >90%.
  • LVOT VT — RBBB or LBBB morphology + inferior axis, early precordial transition (V1-V3). Aortic cusp origin in 20-30%; ablation requires careful coronary mapping.
  • Fascicular VT — RBBB + left axis (posterior fascicle, most common) or RBBB + right axis (anterior fascicle). Verapamil-sensitive. Ablation >95%.

★ Pearl

In a patient with prior MI presenting with stable wide-complex tachycardia at rate 140-180 bpm with LBBB morphology and northwest axis, the pretest probability of VT exceeds 95% — often you do not need a formal Brugada algorithm to commit to VT therapy. The algorithm matters most when structural heart disease is unknown or absent.

⚠ Pitfall

Adenosine 6-12 mg IV is sometimes given as a “diagnostic challenge” in stable wide-complex tachycardia, with the expectation that SVT will terminate while VT will not. This is dangerous: pre-excited AFib (SVT over accessory pathway) or fascicular VT may transiently terminate, falsely reassuring you, and adenosine in pre-excited AFib can accelerate to VF.

Ventricular Tachycardia — Severity Severity scale: Ventricular Tachycardia — Severity Ventricular Tachycardia — Severity Sustained VT CURRENT >30 sec or hemodynamic compromise; immediate treatment Nonsustained VT ≥3 beats but <30 sec; often asymptomatic; structural HD workup Monomorphic Single QRS morphology; scar-related (post-MI, ARVC, sarcoid); ablation effective Polymorphic Variable QRS; ischemia, LQTS (torsades), Brugada, electrolyte; correct underlyin Idiopathic VT Structurally normal heart; RVOT (LBBB+inferior axis), fascicular; ablation curat Criteria: • Symptom severity • Lab abnormalities • Functional status • Complications
Ventricular Tachycardia — Severity

S3. Acute Management and Pharmacologic Termination

Hemodynamic Triage — The First Question

The first decision in any patient with wide-complex tachycardia is hemodynamic stability. ACLS criteria for instability requiring immediate cardioversion: (1) hypotension SBP <90 mmHg, (2) altered mental status, (3) signs of shock (cool extremities, oliguria), (4) ischemic chest pain, (5) acute heart failure. Pulseless VT is treated identically to VF — immediate unsynchronized defibrillation at maximum biphasic energy (200 J), CPR, epinephrine 1 mg IV q3-5min, amiodarone 300 mg IV bolus (or lidocaine 1-1.5 mg/kg), and continued ACLS.

PresentationImmediate ActionEnergy / Dose
Pulseless VT / VFDefibrillation (unsynchronized)200 J biphasic, immediate CPR, ACLS
Unstable monomorphic VT (with pulse)Synchronized cardioversion100 J biphasic (escalate 150, 200 J)
Polymorphic VT (with pulse)Defibrillation (unsynchronized — sync may fail)200 J biphasic
Stable monomorphic VTPharmacologic terminationProcainamide or amiodarone IV

Procainamide — First-Line for Stable Monomorphic VT (PROCAMIO)

The PROCAMIO trial (2017) randomized 74 patients with stable monomorphic VT to procainamide 10 mg/kg IV over 20 minutes vs amiodarone 5 mg/kg IV over 20 minutes. Procainamide terminated VT in 67% within 40 minutes vs amiodarone 38% (p=0.026), with fewer adverse events (9% vs 41%). Major adverse events were hypotension and worsening arrhythmia.

Dose: Procainamide 10 mg/kg IV over 20 min (max 17 mg/kg total). Maintenance: 1-4 mg/min infusion. Stop infusion if QRS widens >50%, QTc >500 ms, or hypotension. Avoid in severe LV dysfunction (negative inotrope), QTc prolongation, or AV block.

Amiodarone — Default in HFrEF and Electrical Storm

Although procainamide outperformed amiodarone in PROCAMIO, amiodarone remains preferred in:

  • Severe LV dysfunction (LVEF <30%)
  • Active myocardial ischemia
  • Electrical storm
  • Refractory VT/VF after defibrillation

Dose: Amiodarone 150 mg IV over 10 min → 1 mg/min × 6h → 0.5 mg/min × 18h. Maximum cumulative 2.2 g/24h. May repeat 150 mg bolus for breakthrough VT. Watch for hypotension during loading (slow infusion or vasopressor support).

Lidocaine — Third-Line, Particularly Ischemic VT

Lidocaine remains useful in suspected ischemic VT or as add-on when amiodarone fails. Dose: Lidocaine 1-1.5 mg/kg IV bolus, may repeat 0.5-0.75 mg/kg q5-10 min (max 3 mg/kg). Maintenance: 1-4 mg/min infusion. Reduce dose by 50% in heart failure, hepatic dysfunction, or age >70. Toxicity: CNS (perioral numbness, tremor, seizures), cardiac (block, asystole).

Polymorphic VT — Differentiate by QT Interval

QT IntervalLikely DiagnosisTreatment
Normal baseline QTAcute ischemia (most common)Beta-blocker, urgent revascularization, lidocaine, amiodarone
Prolonged QT (acquired)Drug-induced TdP, hypoK/hypoMgMagnesium 2g IV, stop offending drug, correct electrolytes, overdrive pacing
Prolonged QT (congenital)Long QT syndrome (LQT1-3)Magnesium, beta-blocker, ICD if recurrent
Normal QT, exercise-triggeredCPVTBeta-blocker (nadolol), flecainide, ICD if survivor of arrest

Torsades de Pointes — Specific Management

Acute treatment:

  1. Magnesium 2 g IV over 1-2 min regardless of serum Mg level; repeat if needed
  2. Defibrillation if hemodynamically unstable
  3. Discontinue offending drug; correct hypokalemia (K+ >4.0) and hypomagnesemia
  4. Overdrive pacing at 90-110 bpm if bradycardia-dependent (most common in acquired LQTS)
  5. Isoproterenol 1-4 mcg/min IV as bridge to pacing (contraindicated in congenital LQTS)

Drugs to Avoid During Acute VT

Never Give in Wide-Complex Tachycardia of Unknown Mechanism

AV nodal blockers — verapamil, diltiazem, adenosine (the latter in pre-excited rhythms), digoxin. In true VT, these provide no benefit and can precipitate hemodynamic collapse. In pre-excited AFib (SVT over accessory pathway), AV nodal blockade increases conduction down the bypass tract and can degenerate to VF. Procainamide IV (if hemodynamically stable) is the safer choice for pre-excited AFib.

Always Look for Reversible Triggers

Every acute VT episode warrants rapid assessment for reversible cause: (1) electrolyte abnormalities (K+, Mg2+, Ca2+), (2) acute coronary syndrome (ECG, troponin, urgent angiography if STEMI), (3) hypoxia, (4) acidosis, (5) drug toxicity (digoxin, QT-prolonging agents), (6) device issues (ICD lead failure, pacemaker malfunction). Reversible-cause VT does not establish indication for ICD secondary prevention — addressing the cause is curative.

Ventricular Tachycardia — Procedure Steps Surgical stepper: Ventricular Tachycardia — Procedure Steps Ventricular Tachycardia — Procedure Steps 1 Acute unstable Pulseless: defibrillate 200J biphasic immediately; with pulse: synchronized 100J biphasic; epinephri 2 Acute stable monomorphic Procainamide 20-50 mg/min IV (max 17 mg/kg) preferred; amiodarone 150mg IV bolus → 1 mg/min × 6h; li 3 Polymorphic VT (torsades) Magnesium 2g IV bolus; correct K+ to 4.5-5.0; isoproterenol 1-3 mcg/min if pause-dependent; overdriv 4 Underlying CV evaluation Echo (LV function), coronary angiography (if ischemic), cardiac MRI (scar, sarcoid), ETT, electrolyt 5 ICD Primary prevention: EF ≤35% + NYHA II-III on optimal Rx; secondary prevention: post-VT/VF arrest wit 6 Ablation Indications: scar-mediated VT despite Rx, electrical storm, idiopathic VT; epicardial mapping if nee
Ventricular Tachycardia — Procedure Steps

S4. ICD Therapy: Primary and Secondary Prevention

Secondary Prevention — Class 1 Indications

Implantable cardioverter-defibrillator (ICD) is the standard of care after surviving an episode of sustained VT/VF without reversible cause. The 2017 AHA/ACC/HRS ventricular arrhythmia guideline recommends ICD (Class 1, Level A) for:

  • Survivors of VT/VF cardiac arrest from any cause not due to reversible mechanism (AVID, CIDS, CASH trials; HR 0.72 vs antiarrhythmics)
  • Sustained VT (with or without syncope) and structural heart disease
  • Sustained VT regardless of substrate, when life expectancy >1 year

Primary Prevention in Ischemic Cardiomyopathy

TrialPopulationLVEF ThresholdOutcome
MADIT-IIPost-MI ≥40 days, NYHA I-III≤30%31% RR ↓ all-cause mortality (HR 0.69)
SCD-HeFTIschemic + non-ischemic CMP, NYHA II-III≤35%23% RR ↓ all-cause mortality (HR 0.77)
DINAMITEarly post-MI (6-40 days)≤35%No mortality benefit early after MI; defer ICD ≥40 days

Class 1 indication: Ischemic cardiomyopathy, LVEF ≤35%, NYHA II-III on ≥3 months optimal GDMT, expected meaningful survival >1 year, ≥40 days post-MI (or ≥90 days post-revascularization).

Primary Prevention in Nonischemic Cardiomyopathy

The DANISH trial (2016) randomized 1,116 patients with NICM and LVEF ≤35% to ICD vs medical therapy. After 5.6 years median follow-up: no all-cause mortality benefit (HR 0.87, 95% CI 0.68-1.12, p=0.28) but a significant 50% reduction in sudden cardiac death (HR 0.50, p=0.005). Subgroup analysis suggested benefit in patients <68 years (HR 0.51 for all-cause mortality, p=0.01).

2017 AHA/ACC/HRS retained Class 1 recommendation for ICD in NICM with LVEF ≤35% on ≥3 months GDMT despite DANISH, particularly for younger patients. CMR with LGE ≥6% is an emerging risk modifier supporting ICD in equivocal cases.

ICD in Special Substrates

ConditionICD ClassRationale
HCM with ≥1 major risk factorClass 2aSCD risk >1% per year; LGE ≥15% modifier
ARVC with sustained VT/syncopeClass 1Progressive RV scar, high recurrence
Cardiac sarcoidosis with LVEF ≤35% or sustained VTClass 1Granulomatous scar substrate
Long QT syndrome — survivor of arrestClass 1Despite beta-blocker, high recurrence
Brugada syndrome — survivor of arrest or spontaneous VFClass 1No reliable medical prevention except quinidine
CPVT — survivor of arrest despite beta-blockerClass 2aICD with caution (shock can trigger storm)

Single vs Dual Chamber and CRT-D

  • Single-chamber ICD: default for most primary-prevention indications; lower lead complication rate
  • Dual-chamber ICD: when concomitant pacemaker indication (sinus node dysfunction, AV block) or for AT/AF discrimination
  • Subcutaneous ICD (S-ICD): consider for younger patients without pacing need, prior endocarditis, or limited venous access
  • CRT-D: LVEF ≤35%, NYHA II-IV ambulatory, LBBB QRS ≥150 ms (Class 1); narrower QRS or non-LBBB has weaker benefit

Programming and Inappropriate Shocks

The MADIT-RIT (2012) and PainFREE (2004) trials showed that high-rate cutoffs (≥200 bpm), prolonged detection durations (≥2.5 sec), and antitachycardia pacing (ATP) reduce inappropriate shocks by 50-80% without increasing syncope or mortality. Standard primary-prevention programming: VF zone ≥200 bpm (5 sec detection), VT zone 188-200 bpm (12 sec detection with ATP), monitor zone 170-188 bpm (no therapy). Inappropriate shocks affect 8-40% of ICD patients; common causes are AFib with rapid response, supraventricular tachycardia, T-wave oversensing, and lead noise.

When to Refer for ICD Evaluation

Refer to electrophysiology for ICD evaluation: (1) any survivor of cardiac arrest, (2) sustained VT episode without reversible cause, (3) ischemic CMP with LVEF ≤35% on ≥3 months GDMT and ≥40 days post-MI, (4) NICM with LVEF ≤35% on ≥3 months GDMT (especially <68 years), (5) HCM with ≥1 major SCD risk factor, (6) inherited channelopathy with high-risk features. Always confirm life expectancy >1 year and patient’s goals of care before implant.

S5. Catheter Ablation and Electrical Storm

Catheter Ablation — From Rescue to First-Line

Catheter ablation has progressively moved from rescue therapy for refractory VT to first-line consideration. Key evidence:

  • VANISH (2016): 259 patients with ischemic VT and ICD shock despite antiarrhythmics randomized to ablation vs escalated drug therapy. Ablation reduced composite death/VT storm/appropriate shock (HR 0.72, p=0.04).
  • SMASH-VT, VTACH: Prophylactic ablation at time of ICD implant in ischemic VT reduced recurrence by 30-50%.
  • PARTITA (2022): Early ablation after first appropriate ICD shock reduced death and worsening HF hospitalization (HR 0.57, p=0.009) compared to deferred ablation.
  • BERLIN-VT (2020): Preventive ablation pre-ICD vs deferred showed no benefit in time to first VT — conflicting with PARTITA, suggesting timing matters.

Class 1 Indications for VT Ablation

  1. Recurrent monomorphic VT with structural heart disease causing ICD shocks despite antiarrhythmic drugs
  2. Incessant VT or electrical storm refractory to drugs
  3. Symptomatic idiopathic VT (RVOT, fascicular) intolerant of or refractory to drugs
  4. Bundle branch reentry VT

Substrate Mapping and Ablation Strategy

Modern VT ablation relies on electroanatomic mapping (CARTO, EnSite, Rhythmia) integrated with pre-procedure CMR or CT to identify:

  • Dense scar (bipolar voltage <0.5 mV) — anatomic conduction block
  • Border zone (0.5-1.5 mV) — slow-conduction channels supporting re-entry
  • Late potentials and local abnormal ventricular activities (LAVAs) — surrogates for slow-conduction channels
  • Channels connecting healthy myocardium through scar — ablation targets

Substrate-based ablation (homogenization of scar, channel transection) has surpassed activation/entrainment mapping alone, particularly for unmappable VT (hemodynamically intolerant, multiple morphologies). Acute success rates: 70-90% for ischemic VT, 50-70% for nonischemic VT (often requires epicardial access). Recurrence at 1 year: 25-35% ischemic, 35-50% nonischemic.

Electrical Storm — Definition and Acute Management

Electrical storm is defined as ≥3 episodes of sustained VT/VF or ≥3 appropriate ICD therapies (shocks or ATP) within 24 hours. It carries 6-month mortality of 15-30% and demands aggressive escalation:

Step 1 — Immediate Stabilization

  • Sedation: Propofol 25-75 mcg/kg/min or Dexmedetomidine 0.2-1.4 mcg/kg/hr — both reduce sympathetic surge
  • Intubation if hemodynamically unstable or refractory
  • Reverse triggers: K+ >4.5, Mg2+ >2.0, treat ischemia/HF
  • Magnetic deactivation of ICD shock therapy if storm provoked by inappropriate shocks (program ATP-only zones first)

Step 2 — Antiadrenergic Therapy

Sympathetic overdrive sustains storm. IV beta-blockade is essential:

  • Esmolol 50-200 mcg/kg/min IV (rapid onset, titratable)
  • Propranolol 1 mg IV q5min × 5 then 1-3 mg q4-6h
  • Amiodarone 150 mg IV bolus → infusion (additive to beta-blocker)

Step 3 — Refractory Storm

  • Stellate ganglion blockade: single-shot bupivacaine 0.5% 5-10 mL ultrasound-guided at C7 level — case series show ≥50% reduction in VT episodes
  • Thoracic epidural anesthesia (T1-T4): for sustained antiadrenergic effect
  • VA-ECMO bridge: for patients in cardiogenic shock or as bridge to emergent ablation
  • Emergency VT ablation: Class 1 indication for incessant VT in structural heart disease

Storm in HFrEF: Avoid Class IC and Pure AV Nodal Blockers

Flecainide and propafenone are contraindicated in structural heart disease (CAST trial — increased mortality post-MI). Pure AV nodal blockers (verapamil, diltiazem) should be avoided in storm — they offer no antiarrhythmic benefit and worsen LV function. Sotalol can be used in storm but requires QTc monitoring; avoid with eGFR <40.

Sympathetic Denervation

Bilateral cardiac sympathetic denervation (BCSD) — surgical resection of T1-T4 sympathetic chain — is increasingly used for refractory VT storm, congenital long QT syndrome, and CPVT not controlled by beta-blockers. Series show 50-90% reduction in arrhythmic events at 1 year. Less invasive than ablation in some cases of polymorphic storm without identifiable substrate.

★ Pearl

In any patient with storm, the first 30 minutes should focus on three parallel actions: (1) heavy sedation with propofol or dexmedetomidine to break the sympathetic loop, (2) IV beta-blockade (esmolol drip is most titratable), and (3) IV amiodarone load. Stellate ganglion block is portable and can be performed at bedside under ultrasound — do not wait for surgical consultation in true refractory storm.

⚠ Pitfall

Repeated ICD shocks in a conscious patient cause severe psychological trauma and post-shock anxiety/PTSD in 20-40%. In storm, deactivate shock therapy temporarily with a magnet (or formal reprogramming) once airway is secured and sedation is deep — this prevents further shocks while you address the underlying mechanism. Do not leave shocks active during ablation procedures.

S7. Practice Insights: Bedside Notes on Ventricular Tachycardia

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A patient sitting up and talking through a wide-complex tachycardia still has ventricular tachycardia most of the time, and blood pressure was never a diagnostic test, so the costliest errors in VT are diagnostic rather than therapeutic. In experienced hands the pivot points are refusing to call wide-complex SVT until experienced clinicians have run Brugada and Vereckei criteria, choosing procainamide over amiodarone in stable patients, and recognizing electrical storm early enough that stellate ganglion blockade still has a window. Experienced practice tracks three things at every bedside: 12-lead morphology compared to baseline, magnesium and potassium even when “normal,” and QTc on whatever drug was just given.

What the Guideline Misses — “Stable” Doesn’t Mean SVT

The guideline lists Brugada criteria but in experienced practice trainees still call hemodynamically stable wide-complex rhythms “probable SVT with aberrancy” by default. Experienced practice now teaches: if the patient is over 50 with any structural heart disease, the prior probability of VT is >90% — and treating SVT first (adenosine, calcium channel blockers) can crash a VT patient. Experienced clinicians assume VT until proven otherwise and reach for procainamide before adenosine.

Patterns Experienced Clinicians Have Seen Repeat — Procainamide Beats Amiodarone Acutely

PROCAMIO showed procainamide superior for acute termination in stable VT, but amiodarone remains the reflex drug in most US ICUs. In practice procainamide 10 mg/kg IV over 20 minutes converts roughly 65-70% of monomorphic VTs in stable patients in experienced hands, versus the more modest amiodarone yield. Seasoned clinicians save amiodarone for shock-refractory, polymorphic VT, or active ischemia where the negative inotropy is acceptable.

VT Storm Bridge — Stellate Ganglion Block

Three or more sustained VT episodes in 24 hours = storm. Standard escalation is amiodarone + beta-blocker + sedation + ablation referral, but in experienced practice left stellate ganglion block (under ultrasound, 10 mL ropivacaine 0.5%) buys hours to days while ablation logistics align. Experienced clinicians have requested it maybe a dozen times in 14+ years — the response in true autonomic-driven storm is often dramatic. Anesthesia colleagues are eager once they see it work.

Bedside Heuristic — Idiopathic VT Means Cure, Not ICD

RVOT VT (LBBB morphology, inferior axis, V1 transition late) and fascicular VT (RBBB, superior axis, verapamil-sensitive) are curable by ablation with success >90% and don’t need ICDs in most patients. Experienced practice pushes for EP referral within days, not weeks — too many of these patients accrue suboptimal beta-blocker trials before ablation is offered. Don’t confuse idiopathic VT with structural VT just because the QRS is wide.

A Case That Reframed the established Approach — Storm in a Recently-Implanted ICD

A man in his late 50s with ischemic cardiomyopathy and EF 28% presented one month after primary-prevention ICD with eight appropriate shocks for monomorphic VT in 12 hours. Amiodarone load was running, beta-blocker maximized, magnesium 2.2, potassium 4.5. The treating clinicians requested left stellate ganglion block; storm broke within 90 minutes and stayed quiet through transfer to the EP lab the next morning for substrate ablation. What experienced clinicians learned: in shock-storm with recently-implanted ICD, don’t wait for the ablation team’s “morning list” — the autonomic surge from each shock is itself proarrhythmic, and the ganglion block can interrupt that loop while logistics settle. Experienced clinicians have used the same sequence three more times since with similar results.

Bedside lesson: in VT storm, escalate beyond pharmacology fast — stellate ganglion block, deep sedation/intubation, and overnight EP transfer beat waiting for “morning” ablation by a wide margin.

Practice Pattern Refinements That Diverge From Standard Guidelines

  1. Procainamide loading at 10 mg/kg over 20 min, not “150 mg over 10 min”. The textbook dose under-loads most adult patients. In experienced hands a 70 kg patient gets ~700 mg over 20 minutes with continuous BP and ECG, halting for hypotension or QRS widening >25%. Conversion rate is meaningfully higher than the conservative dose.
  2. Reflex Mg 2 g IV in every monomorphic VT, even when level is “normal”. Serum magnesium poorly reflects intracellular stores and the cost of 2 g IV is trivial. Experienced practice gives it before procainamide as a matter of routine — Experienced clinicians have watched it terminate borderline cases by itself.
  3. Early QTc surveillance on amiodarone (day 3, day 7), not “as needed”. Amiodarone QTc creep is more aggressive than most teams realize, especially with concurrent hypokalemia. Experienced practitioners schedule ECG at day 3 and day 7 and again after any electrolyte derangement. In published series, about 1 in 8 amiodarone patients develops QTc >500 ms requiring dose pause.
  4. EP ablation referral at the second sustained VT episode in structural heart disease, not after “anti-arrhythmic failure”. VANISH and SMASH-VT signals support ablation early. In published series, these patients waiting for “two antiarrhythmics to fail” accumulate ICD shocks and PTSD; early ablation referral changes that trajectory.
VT Diagnostic and Acute Termination Algorithm Wide-complex tachycardia → assume VT → Brugada/Vereckei → procainamide-first → escalation to storm management VT Algorithm — Assume VT, Procainamide First, Storm-Ready Wide-Complex Tachycardia QRS ≥120 ms, rate >100 the established rule: assume VT until proven otherwise (Brugada + Vereckei criteria, structural heart disease history) UNSTABLE Synchronized 100–200 J cardioversion Sedate first if conscious STABLE monomorphic Procainamide 10 mg/kg IV / 20 min + Mg 2 g IV routinely Refractory / ≥3 in 24h = STORM Amiodarone + βB max + sedate Stellate ganglion block (the move) EP lab — substrate ablation Overnight transfer, not “morning list” ICD if EF ≤35% (DANISH-caveats) Idiopathic VT subset (no structural heart disease) RVOT (LBBB + inferior axis) → ablation 1st-line Fascicular (RBBB + superior axis) → verapamil + ablation non-negotiables every VT K+ >4.5, Mg2+ >2.0, QTc trended day 3 + day 7 on amiodarone Hold any QT-prolonging drug before procainamide Observed: procainamide converts ~65–70% of stable monomorphic VT in experienced hands. — gomdori, MD

S6. Special Populations, Follow-up, and FAQ

Special Populations

PopulationKey Considerations
Elderly (≥80 years)Reduced mortality benefit from primary-prevention ICD (DANISH subgroup); shared decision-making mandatory; consider quality of life, frailty, life expectancy >1 year requirement
End-stage renal diseaseICD benefit attenuated in dialysis (high competing mortality); careful selection; QTc-prolonging agents avoided
PregnancyProcainamide and lidocaine preferred for acute VT; beta-blockers (metoprolol, propranolol) for chronic; avoid amiodarone (fetal hypothyroidism); ICD safe
Channelopathies (LQT, Brugada, CPVT)Genetic testing of probands and first-degree relatives; sport restriction per phenotype; specialized inherited arrhythmia clinic referral
Cardiac sarcoidosisSteroids + ICD; ablation often required; F-18 FDG PET to assess inflammation activity
AthletesPre-participation screening (ECG ± echo per Bethesda criteria); HCM/ARVC/CPVT/LQT confer participation restrictions; shared decision per 2020 ESC sports cardiology guidelines

Long-Term Follow-up After VT/ICD

  • EP clinic visit at 2-4 weeks post-ICD for wound check and device interrogation
  • Routine ICD interrogation every 3-6 months (in-office or remote)
  • Annual echocardiogram to track LV function
  • Optimize GDMT for HF: ARNI, beta-blocker, MRA, SGLT2i — these reduce VT recurrence independently
  • Address depression/PTSD; ICD shock can trigger panic and anticipatory anxiety; refer to cardiac psychology
  • Driving restrictions: 6 months post-secondary prevention ICD or appropriate shock (US AHA/HRS); private driving usually permitted after
  • Battery generator replacement at 5-10 years depending on device and shock burden

GDMT Reduces VT Recurrence

Optimization of heart failure medical therapy independently reduces VT events:

  • Beta-blockers (carvedilol, metoprolol succinate) reduce SCD by 30-40% in HFrEF
  • MRA (spironolactone, eplerenone) reduce SCD by 20-25% (RALES, EMPHASIS-HF)
  • ARNI (sacubitril-valsartan) reduces SCD by 20% over enalapril (PARADIGM-HF)
  • SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce composite CV events including VT (DAPA-HF, EMPEROR-Reduced)

Frequently Asked Questions

How do you differentiate VT from SVT with aberrancy on ECG?
Use the Brugada algorithm: (1) absence of RS in all precordial leads = VT; (2) RS interval >100 ms in any precordial = VT; (3) AV dissociation = VT; (4) morphology criteria for VT in V1-V2 and V6. The Vereckei aVR algorithm asks 4 sequential questions about lead aVR (initial R wave, initial r/q >40 ms, notch on initial downstroke, ventricular activation velocity ratio). When in doubt, treat wide-complex tachycardia as VT — misdiagnosis as SVT and giving AV nodal blockers in true VT can precipitate hemodynamic collapse.
Amiodarone or procainamide for hemodynamically stable monomorphic VT?
Procainamide (PROCAMIO trial) is preferred over amiodarone for stable monomorphic VT in patients without severe LV dysfunction — 67% termination vs 38% with fewer adverse events. Procainamide dose: 10 mg/kg IV over 20 minutes (maintenance 1-4 mg/min). Amiodarone 150 mg IV over 10 min (may repeat) → 1 mg/min × 6h then 0.5 mg/min remains first-line in HFrEF, ischemic VT, and electrical storm. Lidocaine (1-1.5 mg/kg IV bolus) is third-line, particularly in ischemic VT. Avoid procainamide if QTc prolonged or severe HF.
What are the indications for ICD primary prevention in nonischemic cardiomyopathy?
Class 1 (2017 AHA/ACC/HRS): NICM with LVEF ≤35% and NYHA II-III on ≥3 months optimal GDMT, expected survival >1 year. The DANISH trial (2016) found no all-cause mortality benefit for ICD in NICM (HR 0.87, p=0.28) but a significant 50% reduction in sudden cardiac death (HR 0.50, p=0.005). Subgroup analysis suggested benefit in patients <68 years. ICD remains Class 1 in NICM with LVEF ≤35% on GDMT. CMR with late gadolinium enhancement (LGE) ≥6% strongly predicts arrhythmic events and may guide individualized decision-making.
How is electrical storm managed?
Electrical storm = ≥3 sustained VT/VF episodes or ≥3 appropriate ICD shocks within 24 hours. Acute management: (1) sedation (propofol, dexmedetomidine), (2) IV beta-blocker (esmolol 50-200 mcg/kg/min or propranolol 1 mg IV q5min), (3) amiodarone 150 mg IV bolus then infusion, (4) reverse triggers (electrolytes, ischemia, drug toxicity). Refractory storm: deep sedation/intubation, stellate ganglion blockade (single-shot 5-10 mL bupivacaine 0.5% C7 level), thoracic epidural anesthesia, or ECMO bridge to ablation. Emergency catheter ablation is Class 1 for incessant VT in structural heart disease.
When is catheter ablation indicated for VT?
Class 1 indications: (1) recurrent monomorphic VT with structural heart disease causing ICD shocks despite antiarrhythmics, (2) incessant VT or electrical storm refractory to drugs, (3) symptomatic idiopathic VT (RVOT, fascicular). The PARTITA trial (2022) showed early ablation after first appropriate ICD shock reduced death/hospitalization (HR 0.57). The VANISH trial favored ablation over escalated antiarrhythmics in ischemic VT (HR 0.72 for composite endpoint). Acute success ~70-90% for ischemic VT; recurrence ~30% at 1 year. Substrate-based ablation guided by electroanatomic mapping is standard for scar-related VT.
How is torsades de pointes treated and prevented?
Acute treatment: (1) magnesium sulfate 2 g IV over 1-2 minutes (regardless of serum Mg level), repeat if needed; (2) defibrillation if hemodynamically unstable; (3) overdrive pacing or isoproterenol 1-4 mcg/min for bradycardia-induced TdP; (4) discontinue offending QT-prolonging drugs and correct hypokalemia/hypomagnesemia. High-risk drugs: methadone, haloperidol, ondansetron, fluoroquinolones, macrolides, antipsychotics. QTc >500 ms or ΔQTc >60 ms from baseline confers highest risk. For congenital long QT syndrome, beta-blockers (nadolol, propranolol) are first-line; ICD for survivors of cardiac arrest or recurrent syncope despite beta-blockers.
What is the role of CMR in VT risk stratification?
Cardiac MRI with late gadolinium enhancement (LGE) identifies myocardial scar — the substrate for re-entrant VT. In ischemic cardiomyopathy, LGE burden ≥10% of LV mass is independently associated with appropriate ICD therapy (HR 2-4×). In NICM, mid-wall septal LGE pattern predicts SCD even with EF >35%. Hypertrophic cardiomyopathy: LGE ≥15% of LV mass is a major risk modifier in the AHA/ACC HCM SCD risk stratification (Class 2a for ICD when LGE ≥15%). CMR is also essential to identify cardiac sarcoidosis, ARVC, myocarditis, and amyloidosis — etiologies that change SCD risk and therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *